Broker sees 'strong asymmetric upside risk' for ResMed shares

Goldman Sachs is recommending investors snap up this beaten down share.

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have really taken a beating in recent months.

Concerns over the emergence of obesity drugs have weighed heavily on sentiment.

But has this all been a huge overreaction? The team at Goldman Sachs appears to believe that this is the case and is urging investors to snap up the company's shares while they're dirt cheap.

What is Goldman Sachs saying?

Goldman notes that semaglutide (branded as Ozempic, Rybelsus or Wegovy) and tirzepatide (branded as Mounjaro) belong to a class called GLP-1/GIP-receptor agonists.

While these drugs were initially targeting type 2 diabetes, they have consistently demonstrated clear efficacy in weight management and cardiovascular indications.

Given that obstructive sleep apnoea (OSA) is "an indication that is correlated with weight and cardiovascular comorbidities," the broker acknowledges that there are concerns about the impact these drugs could have on demand for ResMed's industry-leading technology.

However, its research shows that the two treatments can grow strongly together over the long term. Particularly given that "OSA remains under-penetrated, with global estimates suggesting <20% and many countries well-below this level."

The base case for ResMed

Goldman has outlined its base case for ResMed in a world with obesity drugs. It explains:

Our base scenario adopts our base case obesity forecasts from above (i.e. -7% reduction in obese or overweight with comorbidity population by 2030E). It then assumes the following patient retention on CPAP (mild 55%; moderate 70%; severe 80%). In this scenario we could see only a modest benefit of AHI [Apnea-Hyponea Index] in GPI-2 over GPI-1, which could result in a lower level of patients.

Overall, we expect continued adoption/success of the GLP-1/GIP class to reduce the OSA population addressable by CPAP, but the impact to RMD/FPH is mitigated by: i) long-term market share gains from competitors; and ii) continued improvements in OSA diagnosis rates (potentially catalysed by the GLP-1/GIP class itself).

ResMed shares have 'strong asymmetric upside'

Goldman highlights that its analysts "see strong asymmetric upside risk from current levels."

According to the note, the broker has reiterated its buy rating on ResMed's shares with a reduced price target of $33. This implies a potential upside of almost 53% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »